Safety of oral incretin treatment

Abstract

Incretin therapy has been used in line with currentguidance in treatment of type 2 diabetes for a fewyears. The efficacy of incretin mimetics and incretinenhancers has been proved in many clinical studiesso far. Since this therapy is available on market thereare concerns regarding its safety. This article is an reviewof current data about safety of DPP-4 inhibitorsin special groups of patients: elderly, prone to hypoglycemia,or with deterioration of kidney function. Itconcerns also on issues associated with cardiovascularrisk, pancreatitis and pancreatic cancer.